Jan. 21, 2021: Dyad-level interventions in serodiscordant relationships; using social media to improve PrEP uptake; HCV prevalence among MSM; the irrelevance of doxycycline prophylaxis against mycoplasma genitalium.
U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light
The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.
Dec. 3, 2020: A simple scoring system for PrEP referral; integrating meth use and HIV prevention interventions; genetically linked HIV strains cross county lines; viral suppression rates in first vs. second pregnancies.
A recent expert debate explored the pros and cons of prescribing the antibiotic as a preventive measure for a subset of people at especially high risk for sexually transmitted infections.
The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.
Oct. 15, 2020: Adherence barriers among Latinx MSM; Atlanta's Ending the HIV Epidemic priorities; Ryan White HIV service coordination; PrEP, white coat dosing, and drug resistance.
Oct. 1, 2020: HIV surveillance trends among U.S. MSM; health insurance and viral suppression; PrEP prescribing among motivated clinicians; PrEP sharing between MSM.
Immediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSM
Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.
Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.
Aug. 20, 2020: HIV knowledge and stigma among health care workers in the southern U.S.; condomless sex vs. HIV risk among MSM; how drug class choice may affect onward transmission risk; STI screening rates among MSM on PrEP.